

Sanja S SoskiÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6932769/publications.pdf>

Version: 2024-02-01

22
papers

793
citations

759055

12
h-index

752573

20
g-index

23
all docs

23
docs citations

23
times ranked

1015
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 117-124.	0.6	6
2	Leptin and Obesity: Role and Clinical Implication. <i>Frontiers in Endocrinology</i> , 2021, 12, 585887.	1.5	363
3	Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery. <i>Frontiers in Endocrinology</i> , 2021, 12, 758043.	1.5	9
4	Effects of IGF-1 on the Cardiovascular System. <i>Current Pharmaceutical Design</i> , 2019, 25, 3715-3725.	0.9	22
5	Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors' Reply). <i>Angiology</i> , 2017, 68, 561-561.	0.8	2
6	Interrelatedness between C-reactive protein and oxidized low-density lipoprotein. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 29-34.	1.4	26
7	High-Sensitivity C-Reactive Protein and Statin Initiation. <i>Angiology</i> , 2015, 66, 503-507.	0.8	1
8	Obesity and Vitamin D Deficiency. <i>Angiology</i> , 2015, 66, 237-243.	0.8	41
9	Vitamin D and Dysfunctional Adipose Tissue in Obesity. <i>Angiology</i> , 2015, 66, 613-618.	0.8	28
10	The impact of obesity on development of cardiovascular diseases: Mini review. , 2015, 49, 33-35.		0
11	Leptin and its mechanism of action. , 2015, 49, 36-41.		0
12	Association of leptin gene polymorphism <i>G-2548A</i> with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study. <i>Clinical Lipidology</i> , 2014, 9, 505-513.	0.4	2
13	The relationship between vitamin D and obesity. <i>Current Medical Research and Opinion</i> , 2014, 30, 1197-1199.	0.9	31
14	A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin. <i>Current Pharmaceutical Design</i> , 2013, 19, 4953-4963.	0.9	22
15	Peroxisome Proliferator-Activated Receptors and Atherosclerosis. <i>Angiology</i> , 2011, 62, 523-534.	0.8	28
16	Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 153-163.	0.6	126
17	Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2011, 17, 3699-3712.	0.9	19
18	Effect of Insulin on Adiponectin and Adiponectin Receptor-1 Expression in Rats with Streptozotocin-induced Type 2 Diabetes. <i>Journal of Health Science</i> , 2011, 57, 334-340.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. <i>Journal of Physiology and Biochemistry</i> , 2011, 67, 195-204.	1.3	29
20	Levels of sCD40 Ligand in Chronic and Acute Coronary Syndromes and its Relation to Angiographic Extent of Coronary Arterial Narrowing. <i>Angiology</i> , 2010, 61, 567-573.	0.8	10
21	Insulin, Thrombin, ERK1/2 Kinase and Vascular Smooth Muscle Cells Proliferation. <i>Current Pharmaceutical Design</i> , 2010, 16, 3895-3902.	0.9	24
22	Pro12Ala gene polymorphism in the peroxisome proliferator-activated receptor gamma as a risk factor for the onset of type 2 diabetes mellitus in the Serbian population. <i>Archives of Biological Sciences</i> , 2010, 62, 263-270.	0.2	2